Impact News +++ Quartalszahlen: CoreWeave verdoppelt Umsatz, kämpft aber mit steigenden Verlusten (IT-Times) +++ COREWEAVE Aktie -6,85%

PACIRA Aktie

>PACIRA Aktienkurs

17.8 EUR -7.3% (TradegateBSX)

Ask: 18.5 EUR / 540 Stück

Bid: 18.4 EUR / 550 Stück

Tagesumsatz: 2080 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

PACIRA Aktie über LYNX handeln

Intraday

1 Jahr

>PACIRA Performance

1 Woche: +2,1%

1 Monat: +17,1%

3 Monate: -2,9%

6 Monate: -10,8%

1 Jahr: -16,4%

laufendes Jahr: -10,0%

>PACIRA Aktie

Name:

PACIRA BIOSCIENC. DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US6951271005 / A1H68T

Symbol/ Ticker:

82P (Frankfurt) / PCRX (NASDAQ)

Kürzel:

FRA:82P, ETR:82P, 82P:GR, NASDAQ:PCRX

Index:

Webseite:

http://www.pacira.com/

Profil:

Pacira BioSciences Inc. is a pharmaceutical company focused on delivering non-opioid pain management solutions. Its flagship product, EXPAREL, is a long-acting, local analgesic that releases bupivacai..
>Volltext..

Marktkapitalisierung:

855.07 Mio. EUR

Unternehmenswert:

1007.66 Mio. EUR

Umsatz:

607.27 Mio. EUR

EBITDA:

123.46 Mio. EUR

Nettogewinn:

18.16 Mio. EUR

Gewinn je Aktie:

0.4 EUR

Schulden:

360.33 Mio. EUR

Liquide Mittel:

125.04 Mio. EUR

Operativer Cashflow:

119.83 Mio. EUR

Bargeldquote:

2.3

Umsatzwachstum:

-2.13%

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 352.943 USD.

Suchwörter:

PACIRA

Letzte Datenerhebung:

27.02.26

>PACIRA Kennzahlen

Aktien/ Unternehmen:

Aktien: 43.02 Mio. St.

Frei handelbar: 95.77%

Leerverk. Aktien: 17.86%

Rückkaufquote: 9.67%

Mitarbeiter: 790

Umsatz/Mitarb.: 0.75 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 28.67%

Bewertung:

KGV: 51.82

KGV lG: 6.83

KUV: 1.34

KBV: 1.37

PEG-Ratio: -

EV/EBITDA: 8.16

Rentabilität:

Bruttomarge: 71.17%

Gewinnmarge: 2.99%

Operative Marge: 7.64%

Managementeffizenz:

Gesamtkaprendite: 1.52%

Eigenkaprendite: 2.9%

>PACIRA Peer Group

Gesundheit

>PACIRA Chart & Kurs - NASDAQ

>PACIRA News

27.02.26 - 03:15	Compared to Estimates, Pacira (PCRX) Q4 Earnings: A Look at Key Metrics (Zacks)
	While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....

27.02.26 - 02:00	Pacira outlines $745M–$770M 2026 revenue target as 5x30 strategy drives margin and pipeline progress (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.02.26 - 01:00	Pacira (PCRX) Lags Q4 Earnings and Revenue Estimates (Zacks)
	Pacira (PCRX) delivered earnings and revenue surprises of -32.74% and -0.06%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...

27.02.26 - 00:12	Pacira (PCRX) Q4 2025 Earnings Call Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

26.02.26 - 23:42	Pacira Pharmaceuticals verfehlt Gewinnprognose für Q4 2025 (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

26.02.26 - 23:21	Pacira Biosciences slips as 2026 revenue guidance, Q4 2025 results disappoint (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

26.02.26 - 22:36	Pacira BioSciences Non-GAAP EPS of $0.57 misses by $0.33, revenue of $196.9M misses by $5.03M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

26.02.26 - 22:03	Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire EN)
	— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years —...

12.02.26 - 22:06

Pacira to Report 2025 Financial Results on Thursday February 26, 2026 (GlobeNewswire EN)

BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2025 financial results after the close of the U.S. markets on Thursday February 26, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET....

12.02.26 - 14:03	Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices (GlobeNewswire EN)
	BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted new survey findings released by the Voices for Non-Opioid Choices (Voices) coalition following the first year of the Non-Opioids Prevent Addiction (“NOPAIN”) Act....

11.02.26 - 09:33	AmacaThera Named Life Sciences Ontario Emerging Company of the Year (PR Newswire)
	Recognition of AmacaThera's leadership and landmark agreement with Pacira BioSciences for its long‑acting, opioid‑sparing anesthetic in post‑operative pain management Progressing AMT-143 to Phase 2 clinical development in 2026 TORONTO, Feb. 11, 2026 /PRNewswire/ -- AmacaThera, a leading......

09.02.26 - 14:03

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)

BRISBANE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on February 3, 2026 to 14 new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval....

04.02.26 - 03:02	Insiderhandel: Chief Administrative Officer verkauft Aktien von Pacira BioSciences im Wert von 269703 USD (Insiderkauf)
	Williams, Kristen Marie - Vorstand - Tag der Transaktion: 2026-02-02...

04.02.26 - 03:02	Insiderhandel: Senior Vice President, Finance verkauft Aktien von Pacira BioSciences im Wert von 83240 USD (Insiderkauf)
	Riker, Lauren Bullaro - Vorstand - Tag der Transaktion: 2026-02-02...

28.01.26 - 14:03

Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors (GlobeNewswire EN)

-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the appointment of Samit Hirawat, M.D., to its Board of Directors. This appointment increases the size of the company's Board of Directors to 10 members....

27.01.26 - 20:30	Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
	Pacira (PCRX) could produce exceptional returns because of its solid growth attributes....

27.01.26 - 19:45	Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
	Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report....

16.01.26 - 16:00	Do Options Traders Know Something About Pacira BioSciences Stock We Don′t? (Zacks)
	Investors need to pay close attention to PCRX stock based on the movements in the options market lately....

14.01.26 - 18:15	PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific (Zacks)
	Pacira BioSciences teams up with LG Chem to expand Exparel across Asia-Pacific, unlocking royalties and new revenue channels to support international growth....

13.01.26 - 14:03	Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets (GlobeNewswire EN)
	-- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy–...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das Leben ein Gedicht! Nein! Nicht wenn man nur umherging und an seinem Leben herumdichtete, anstatt es zu leben. - Jens Peter Jacobsen

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram